©TheCanadian Journal ofUrology™: International Supplement, April 2014
6
Currentmanagement of advanced and castration resistant prostate cancer
References
1. Tilki D, Evans CP. The changing landscape of advanced and
castration resistant prostate cancer: latest science and revised
definitions.
Can JUrol
2014;21(Suppl 1):7-13.
2. Pezaro C, Omlin A, Lorente D, de Bono J. Management of
patients with castration-resistant disease.
Hematol Oncol Clin
NorthAm
2013;27(6):1243-1260.
3. DjavanB, Eastham J, GomellaLet al. Testosterone inprostate
cancer: theBethesda consensus.
BJU Int
2012;110(3):344-352.
4. Rove KO, Crawford ED. Traditional androgen ablation
approachestoadvancedprostatecancer:new insights.
CanJUrol
2014;21(Suppl 1):14-21.
5. Moul JW. Utility of LHRH antagonists for advanced prostate
cancer.
Can JUrol
2014;21(Suppl 1):22-27.
6. AlbertsenPC,KlotzL, TombalB,Grady J,OlesenTK,Nilsson J.
Cardiovascularmorbidityassociatedwithgonadotropinreleasing
hormoneagonistsandanantagonist.
EurUrol
2014;65(3):565-573.
7. Gandaglia G, SunM, Popa I et al. The impact of the androgen
deprivationtherapyontheriskofcoronaryheartdiseaseinpatients
withnon-metastaticprostatecancer:apopulation-basedstudy.
BJU
Int
2014Mar10.doi: 10.1111/bju.12732. [Epubaheadofprint].
8. Dason S, Allard CB, Wang JG, Hoogenes J, Shayegan B.
Intermittentandrogendeprivation therapy forprostatecancer:
translating randomized controlled trials into clinical practice.
Can JUrol
2014;21(Suppl 1):28-36.
9. Small EJ, Vogelzang NJ Second-line hormonal therapy for
advanced prostate cancer: a shifting paradigm.
J Clin Oncol
1997;15(1):382-388.
10.Al-AsaaedS,WinquistE.Secondaryhormonalmanipulation in
castrationresistantprostatecancer.
Can JUrol
2014;21(Suppl1):
37-41.
11. Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B,
HussainA.Theeconomicburdenofskeletal-relatedeventsamong
elderlymenwithmetastaticprostate cancer.
Pharmacoeconomics
2014;32(2):173-191.
12.GomellaLG,Gelpi-HammerschmidtF,KundavramC.Practical
guidetoimmunotherapyincastrationresistantprostatecancer:the
useofsipuleucel-T immunotherapy.
CanJUrol
2014;21(Suppl1):
48-56.
13.Crawford ED, Stone NN, Yu EY et al. Challenges and
recommendations for early identificationofmetastaticdisease
inprostate cancer.
Urology
2014;83(3):664-669.
14.Leung D, Krishnamoorthy S, Schwartz L, Divgi C. Imaging
approaches with advanced prostate cancer: techniques and
timing.
Can JUrol
2014;21(Suppl 1):42-47.
15.SchweizerMT,DrakeCG Immunotherapy forprostate cancer:
recent developments and future challenges.
CancerMetastasis
Rev
2014 Jan 30. [Epub aheadof print].
16.Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T
immunotherapy forcastration-resistantprostatecancer.
NEngl
JMed
2010;363(5):411-422.
17.Goyal J,Antonarakis ES. Clinical evaluation of abiraterone in
the treatment of metastatic prostate cancer.
ClinMed Insights
Urol
2013;2013(7):1-14.
18.MostaghelEA,LinDW.Practicalguide to theuseofabiraterone in
castrationresistantprostatecancer.
CanJUrol
2014;21(Suppl1):57-63.
19.RathkopfD,ScherHI.Androgenreceptorantagonistsincastration-
resistantprostatecancer.
Cancer J
2013;19(1):43-49.
20.Beer TM et al. Enzalutamide inmenwith chemotherapy-naïve
metastaticprostatecancer (mCRPC):ResultsofPhase3PREVAIL
Study American Society of Clinical Oncology (ASCO) 2014
Genitourinary(GU)CancersSymposiumJan30,2014SanFrancisco.
21.Hoffman-Censits J, Kelly WK. Practical guide to the use of
enzalutamide.
Can JUrol
2014;21(Suppl 1):64-69.
22.Brady D, Parker CC, O’Sullivan JM. Bone-targeting radio-
pharmaceuticals includingradium-223.
CancerJ
2013;19(1):71-78.
23.Mohler JL, Kantoff PW, Armstrong AJ et al. Prostate cancer,
version 1.2014.
JNatl ComprCancNetw
2013;11(12):1471-1479.
24.DenRB, Doyle LA, KnudsenKE. Practical guide to the use of
radium 223dichloride.
Can JUrol
2014;21(Suppl 1):70-76.
25.Docetaxel package insert available at:http://dailymed.nlm.
nih.gov/dailymed/lookup.cfm?setid=e03d1378-6889-43d5-
a34c-f96132cffa88.
26.Petrylak DP. Practical guide to the use of chemotherapy in
castrationresistantprostatecancer.
Can JUrol
2014;21(Suppl1):
77-83.
27.Cabazitaxel package insert availableat:
.
nih.gov/dailymed/lookup.cfm?setid=de3d9c26-572b-4ea4-
9b2d-dd58a2b3e8fa.
28.NIH-funded study shows increased survival in men with
metastatic prostate cancer who receive chemotherapy when
startinghormonetherapyhttp://www.cancer.gov/newscenter/
newsfromnci/2013/E3805 (PostedDecember 5, 2013).
29.Butoescu V, Tombal B. Practical guide to bone health in the
spectrumofadvancedprostatecancer.
CanJUrol
2014;21(Suppl1):
84-92.
30.HeidenreichA, BastianPJ, Bellmunt J et al. EAUguidelineson
prostate cancer. Part II: Treatment of advanced, relapsing, and
castration-resistantprostatecancer.
EurUrol
2014;65(2):467-479.
31.DreicerR.How toapproachsequencing therapy inpatientswith
metastatic castration resistant prostate cancer.
Can JUrol
2014;
21(Suppl 1):93-97.
32.Thoreson GR, Gayed BA, Chung PH, Raj GV. Emerging
therapies incastrationresistantprostatecancer.
Can JUrol
2014;
21(Suppl 1):98-105.
33.RyanCJ, SmithMR, deBono JSet al.Abiraterone inmetastatic
prostate cancerwithout previous chemotherapy.
NEngl JMed
2013;368(2):138-148.
34.ParkerC,NilssonS,HeinrichDetal.Alphaemitterradium-223
and survival inmetastatic prostate cancer.
NEngl JMed
2013;
369(3):213-223.
35.de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and
increasedsurvivalinmetastaticprostatecancer.
NEnglJMed
2011;
364(21):1995-2005.
36.Scher HI, Fizazi K, Saad F et al. Increased survival with
enzalutamideinprostatecancerafterchemotherapy.
NEnglJMed
2012;367(13):1187-1197.
37.Bahl A, Oudard S, Tombal B et al. Impact of cabazitaxel on
2-year survival and palliation of tumour-related pain inmen
withmetastatic castration-resistant prostate cancer treated in
theTROPIC trial.
AnnOncol
2013;24(9):2402-2408.
38.Tannock IF,deWitR,BerryWRetal.Docetaxelplusprednisone
ormitoxantroneplusprednisone foradvancedprostatecancer.
NEngl JMed
2004;351(15):1502-1512.
39.SaadF,HotteS,CattonC, et al.CUA-CUOGguidelines for the
management of castration-resistant prostate cancer (CRPC):
2013update.
CanUrolAssoc J
2013;7(7-8):231-237.
40.Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant
prostate cancer:AUAGuideline.
JUrol
2013;190(2):429-438.
Disclosure
Dr.LeonardG.GomellaservesasaconsultanttoAstellas,
Bayer, Dendreon and Janssen. Dr. Daniel P. Petrylak
has received consulting fees from Bayer, Bellicum,
Dendreon, Sanofi Aventis, Johnson and Johnson,
Exelixis, Ferring, Millineum, Medivation and Pfizer.
He also has received grant support fromOncogenex,
Progenics, Johnson and Johnson, Millineum, Celgene
andDendreon. Dr. Bobby Shayegan has no relevant
financial relationships todisclose.
